KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Edwards Lifesciences (EW) EBT (2016 - 2026)

Edwards Lifesciences has reported EBT over the past 17 years, most recently at $90.4 million for Q4 2025.

  • For Q4 2025, EBT fell 76.83% year-over-year to $90.4 million; the TTM value through Dec 2025 reached $1.3 billion, down 17.78%, while the annual FY2025 figure was $1.3 billion, 17.78% down from the prior year.
  • EBT for Q4 2025 was $90.4 million at Edwards Lifesciences, down from $348.4 million in the prior quarter.
  • Over five years, EBT peaked at $545.5 million in Q2 2021 and troughed at $90.4 million in Q4 2025.
  • A 5-year average of $373.6 million and a median of $389.7 million in 2021 define the central range for EBT.
  • Biggest five-year swings in EBT: skyrocketed 424.32% in 2021 and later plummeted 76.83% in 2025.
  • Year by year, EBT stood at $376.3 million in 2021, then plummeted by 43.82% to $211.4 million in 2022, then surged by 73.7% to $367.2 million in 2023, then grew by 6.24% to $390.1 million in 2024, then plummeted by 76.83% to $90.4 million in 2025.
  • Business Quant data shows EBT for EW at $90.4 million in Q4 2025, $348.4 million in Q3 2025, and $400.2 million in Q2 2025.